血液静止生物マーカー評価は,化学療法中に静脈血栓栓症のリスクが高い乳がん患者を特定します
Marina Marchetti1,2, Patricia Gomez-Rosas1,3,4, Laura Russo1
1Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, 24127 Bergamo, Italy.
Cancers
|August 28, 2025
まとめ
転移性乳がん患者における静脈血栓塞栓症 (VTE) の新たなリスク評価モデル (RAM) が,キ-67とフィブリノゲン濃度を用いて開発された. このモデルは,高リスクの個人を正確に特定し,パーソナライズされた血栓予防戦略を支援します.
科学分野:
- 腫瘍学
- 血液学
- トロンボシス 研究
背景:
- 転移性乳がんは,特に化学療法中に静脈血栓塞栓症 (VTE) のリスクを大幅に高めます.
- 現存するリスク評価モデル (RAMs) は,これらの患者のVTEを予測するのに不十分です.
- 転移性乳がんに対する 専用のVTE予測モデルが不可欠です
研究 の 目的:
- 新たに診断された転移性乳がん患者のVTEを予測するための新しいリスク評価モデル (RAM) の開発と検証
- この集団におけるVTEの主要な臨床的および生物学的な予測要因を特定する.
- 現在有効なモデルを超えてリスクの階層化を改善する.
主な方法:
- 転移性乳がん患者189人を対象に実施された前向きな多センター観察試験.
- D- ダイマー,フィブリノゲン,FVIII,プロトロンビン断片1+2,およびトロンビン生成のための血液サンプル分析によるVTEと死亡率のモニタリング
- 競合するリスク分析と多変数回帰により,有意なVTE予測因子を特定する.
主要な成果:
- 1年間の累積的なVTE発生率と死亡率はそれぞれ7. 0%と12%でした.
- Ki-67とフィブリノゲンのレベルは,VTEの最も有意な予測因子として特定されました.
- Ki-67とフィブリノゲンを基に開発されたRAMは,c統計値0. 78を達成し,患者を低リスクと高リスクのVTEグループに分類しました (2%対13%).
結論:
- Ki-67とフィブリノゲンを用いて,転移性乳がんにおけるVTEリスクに対する新しい,正確なRAMが開発されました.
- このモデルは,高リスク患者の正確な識別を可能にし,個別化された血栓予防を容易にします.
- 外部検証は,このリスク分層化ツールの臨床実施を支援するために推奨されます.
関連する概念動画
01:30Venous Thrombosis IV: Nursing Management
22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
01:30Venous Thrombosis I: Introduction
40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
44
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
44